

Ruth Lopert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2817433/publications.pdf>

Version: 2024-02-01

50
papers

1,234
citations

430874

18
h-index

377865

34
g-index

50
all docs

50
docs citations

50
times ranked

1540
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. <i>BMJ Quality and Safety</i> , 2022, 31, 179-190.	3.7	6
2	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. <i>Drug Safety</i> , 2022, , 1.	3.2	2
3	A sorry tale of unnecessary secrecy about medicine safety. <i>Internal Medicine Journal</i> , 2021, 51, 1765-1766.	0.8	0
4	Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 8-11.	0.5	21
5	Financial costs associated with monopolies on biologic medicines in Australia. <i>Australian Health Review</i> , 2019, 43, 36.	1.1	16
6	Japan's emerging role in the global pharmaceutical intellectual property regime: A tale of two trade agreements. <i>Journal of World Intellectual Property</i> , 2018, 21, 88-103.	0.6	7
7	The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries. <i>Global Social Policy</i> , 2018, 18, 7-27.	1.9	29
8	The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam. <i>Global Public Health</i> , 2018, 13, 400-413.	2.0	5
9	Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States. <i>Globalization and Health</i> , 2018, 14, 101.	4.9	18
10	High-Expenditure Pharmaceutical Use Among Children in Medicaid. <i>Pediatrics</i> , 2017, 140, .	2.1	19
11	Pharmaceutical Policy in Bulgaria. , 2017, , 151-168.		0
12	The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines. <i>Asia-Pacific Journal of Public Health</i> , 2016, 28, 682-693.	1.0	15
13	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. <i>Value in Health</i> , 2016, 19, 921-928.	0.3	203
14	Pharma's next frontier? New threats to public health in the Regional Comprehensive Economic Partnership agreement. <i>Australian and New Zealand Journal of Public Health</i> , 2016, 40, 5-6.	1.8	4
15	Pharmacoeconomics as a Response to Market Failure: An International Perspective. , 2016, , 269-279.		0
16	Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific Partnership Agreement. <i>Medical Journal of Australia</i> , 2015, 202, 306-308.	1.7	22
17	How the Transnational Pharmaceutical Industry Pursues its Interests Through International Trade and Investment Agreements: A Case Study of the Trans Pacific Partnership. <i>SSRN Electronic Journal</i> , 2015, , .	0.4	2
18	Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review. <i>Pharmacoeconomics</i> , 2015, 33, 905-924.	3.3	72

#	ARTICLE	IF	CITATIONS
19	Costs of New Treatments for Hepatitis C Infection. JAMA - Journal of the American Medical Association, 2014, 312, 2168.	7.4	2
20	Revolution then evolution: The advance of health economic evaluation in Australia. Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2014, 108, 360-366.	0.9	1
21	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. European Journal of Health Economics, 2014, 15, 27-34.	2.8	14
22	Reply by authors. Health Policy, 2014, 116, 236-237.	3.0	0
23	Applying rapid "de-facto" HTA in resource-limited settings: Experience from Romania. Health Policy, 2013, 112, 202-208.	3.0	26
24	How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand. Health Policy, 2013, 112, 227-233.	3.0	32
25	Biosimilars And The European Experience: Implications For The United States. Health Affairs, 2013, 32, 1803-1810.	5.2	32
26	Australia's "Fourth Hurdle" Drug Review Comparing Costs And Benefits Holds Lessons For The United States. Health Affairs, 2013, 32, 778-787.	5.2	17
27	Intussusception Risk and Disease Prevention Associated With Rotavirus Vaccines in Australia's National Immunization Program. Clinical Infectious Diseases, 2013, 57, 1427-1434.	5.8	178
28	The High Price of "Free" Trade: U.S. Trade Agreements and Access to Medicines. Journal of Law, Medicine and Ethics, 2013, 41, 199-223.	0.9	58
29	Willingness To Pay For Cancer Therapy. Health Affairs, 2012, 31, 1909-1909.	5.2	1
30	Medication Information for Patients with Limited English Proficiency: Lessons from the European Union. Journal of Law, Medicine and Ethics, 2012, 40, 1025-1033.	0.9	7
31	Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes. Value in Health, 2012, 15, 404-411.	0.3	10
32	Persistence in health behaviors among Medicare beneficiaries. Open Journal of Preventive Medicine, 2012, 02, 49-58.	0.3	0
33	Medication adherence and Medicare expenditure among beneficiaries with heart failure. American Journal of Managed Care, 2012, 18, 556-63.	1.1	20
34	Does Medication Adherence Lower Medicare Spending among Beneficiaries with Diabetes?. Health Services Research, 2011, 46, 1180-1199.	2.0	34
35	Panvax febrile reactions not a predictor. BMJ: British Medical Journal, 2010, 341, c3714-c3714.	2.3	0
36	Comparative Effectiveness Research and Evidence-Based Health Policy: Experience from Four Countries. Milbank Quarterly, 2009, 87, 339-367.	4.4	124

#	ARTICLE	IF	CITATIONS
37	PBS copayments and safety nets - A commentary on Sweeny and Doran and Robertson. Australian Health Review, 2009, 33, 241.	1.1	0
38	Medicines and markets: the USA and Australia. Australian Prescriber, 2009, 32, 90-91.	1.0	0
39	Evidence-based decision-making within Australia's pharmaceutical benefits scheme. Issue Brief (Commonwealth Fund), 2009, 60, 1-13.	0.9	18
40	Toward A Rational, Value-Based Drug Benefit For Medicare. Health Affairs, 2007, 26, 1666-1673.	5.2	10
41	Prices for Innovative Pharmaceutical Products That Provide Health Gain: A Comparison Between Australia and the United States. Value in Health, 2007, 10, 514-520.	0.3	25
42	International Price Comparisons for Novel and Follow-on Drugs: A Response. Value in Health, 2007, 10, 512-513.	0.3	1
43	What is Fair? Choice, Fairness, and Transparency in Access to Prescription Medicines in the United States and Australia. Journal of Law, Medicine and Ethics, 2007, 35, 643-656.	0.9	8
44	Differential pricing of drugs: a role for cost-effectiveness analysis?. Lancet, The, 2002, 359, 2105-2107.	13.7	34
45	The Pharmaceutical Benefits Scheme: economic evaluation works...but is not a panacea. Australian Prescriber, 2002, 25, 126-127.	1.0	8
46	Pharmacoeconomics and policy decisions: The Australian health care system. Clinical Therapeutics, 1999, 21, 909-915.	2.5	5
47	A Randomized Controlled Trial of Piroxicam in the Management of Acute Ankle Sprain in Australian Regular Army Recruits. American Journal of Sports Medicine, 1997, 25, 544-553.	4.2	78
48	Drug-Induced Delirium. Drug Safety, 1996, 15, 291-301.	3.2	47
49	Assessing the Impact of Alternative Patent Systems on the Cost of Health Care: The TPPA and HIV Treatment in Vietnam. SSRN Electronic Journal, 0, , .	0.4	3
50	Pharma's Next Frontier? New Threats to Public Health in the Regional Comprehensive Economic Partnership Agreement. SSRN Electronic Journal, 0, , .	0.4	0